Kyverna Therapeutics, Inc. (Kyverna) a California-based clinical-stage biopharmaceutical company, announced on Monday that the US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for the company's autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell product candidate, KYV-101, intended for the treatment of patients suffering from refractory stiff-person syndrome, a rare autoimmune disease.
KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate for use in B cell-driven autoimmune diseases. The CAR in KYV-101 was designed by the National Institutes of Health (NIH) to improve tolerability and tested in a 20-patient Phase 1 trial in oncology. Results were published by the NIH in Nature Medicine.
KYV-101 is currently being evaluated in sponsored, open-label, Phase 1/2 and Phase 2 trials of KYV-101 in the United States and Germany across two broad areas of autoimmune disease: rheumatology and neurology.
Amanda Piquet, MD, director of the Autoimmune Neurology Program at CU Anschutz Medical Campus, Aurora, Colorado, said, 'Stiff-person syndrome has devastating and life-altering effects on patients suffering from this rare autoimmune disease. I look forward to the data that will emerge from the KYSA-8 trial as this trial could drastically change the treatment landscape for SPS.'
Merck discontinues Phase 3 trials KEYNOTE-867 and KEYNOTE-630
Oncosure introduces Rapid Cancer Screening Test
Bayer and NextRNA collaborate on LncRNA-targeting therapeutics
GSK welcomes Delaware Supreme Court review of Zantac litigation
Fusion Antibodies expands collaboration with US National Cancer Institute
Telix Pharmaceuticals submits TLX101-CDx NDA to US FDA
Astellas initiates Phase 3 study for fezolinetant in breast cancer patients
Cantargia updates clinical trial timelines for nadunolimab
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation